ClinicalTrials.gg
Active, not recruitingNCT03742102BEGONIAUpdated Nov 12, 2026Results posted

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

A Phase 1/2 interventional study of Durvalumab and Capivasertib in Triple Negative Breast Neoplasms, sponsored by AstraZeneca. Active, not recruiting at 32 sites in 6 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
243
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing paclitaxel in Triple Negative Breast Neoplasms — 18 open to participants now, 29 under way, 4 of them phase 3. Paclitaxel · Triple Negative Breast Neoplasms.

Enrollment
9th of 63
243 · median 55
Started
2018
with 1 other
Phase 1/2
6 of 63
2 open now
Primary completion
2024-11
later than 4 of 28 live
Registered
28th of 63
by date

Among the 63 studies testing paclitaxel in Triple Negative Breast Neoplasms, this one is the 9th largest by enrollment, is one of 2 that started in 2018, is one of 6 in phase 1/2, reaches primary completion later than 4 of the 28 other live ones, and was the 28th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

18 of the 63 studies testing paclitaxel in Triple Negative Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing paclitaxel in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer

Read the detailed description

This is a Phase IB/II, 2-stage, open-label, multicenter study to determine the efficacy and safety of durvalumab in combination with novel oncology therapies (i.e. therapies designed for immune modulation) with or without paclitaxel and durvalumab + paclitaxel as first-line treatment in patients with metastatic triple negative breast cancer (TNBC). The study is designed to concurrently evaluate potential novel treatment combinations with clinical promise using a 2-stage approach. The study will use a Simon 2-Stage design to evaluate which cohorts may proceed to expansion.

Part 1 is a Phase IB study of safety and initial efficacy, and Part 2 may expand patient enrollment if adequate efficacy signal is observed in Part 1. The treatment regimens evaluated in Part 2 will depend on the evaluation of safety and efficacy outcomes in Part 1.

03

Conditions studied

  • Triple Negative Breast Neoplasms

Keywords

  • Breast Cancer
  • TNBC
  • Triple Negative
  • Triple Negative Breast Cancer
  • Triple-Negative Breast Cancer
  • Triple-Negative Breast Neoplasm
  • ER-Negative PR-Negative HER2-Negative Breast Cancer
  • ER-Negative PR-Negative HER2-Negative Breast Neoplasms
  • PD-L1 high TNBC
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female
  2. At least 18 years of age at the time of screening
  3. Patient must have locally confirmed advanced/unresectable or TNBC.
  4. No prior treatment for metastatic (Stage IV) TNBC
  5. Patient must have at least 1 lesion, not previously irradiated, that can be accurately measured
  6. status at 0 or 1 at enrollment

Patients enrolled to Arm 6 (durvalumab and DS-8201a) Must provide documentation of locally determined advanced/unresectable or metastatic TNBC with low tumor expression (IHC 2+/ISH-, IHC 1+/ISH-, or IHC 1+/ISH untested)

Patients enrolled in Arm 8 (durvalumab + Dato-DXd) Must have positive tumor as determined by an IHC based assay

Exclusion criteria

Exclusion criteria

  1. History of allogeneic organ transplantation
  2. Active or prior documented or inflammatory disorders
  3. Active infection including tuberculosis, (known positive HBV surface antigen [HBsAg] result), virus (HCV), or (positive HIV 1/2 antibodies)
  4. Untreated
  5. Known allergy or to any of the study drugs or any of the study drug
  6. Any concurrent chemotherapy, IP, or biologic therapy for cancer treatment
  7. Female patients who are pregnant, breastfeeding
  8. Cardiac less than 50%

Patients enrolled in Arm 2 only:

  1. Potent inhibitors or inducers or substrates of or substrates of CYP2C9 or CYP2D6 within 2 weeks before the first dose of study treatment (3 weeks for St John's Wort)
  2. Diagnosis of diabetes mellitus Type I or diabetes mellitus Type II requiring insulin treatment.
  3. Any factors that increase the risk of prolongation or risk of arrhythmic events, such as heart failure, hypokalemia, potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age, or any concomitant medication known to prolong the QT interval
  4. Prior treatment with PI3K inhibitors, AKT inhibitors, or mammalian target of rapamycin (mTOR) inhibitors.

Patients enrolled in Arm 5 only: History of venous thromboembolism in the past 3 months

Patients enrolled in Arm 7 and 8 only: corneal disease in the opinion of the Investigator.

Patients enrolled in Arm 6, 7 and 8 only:

  1. History of or active interstitial lung disease/pneumonitis
  2. Use of chloroquine or hydroxychloroquine in \<14 days prior to Day 1 of DS-8201a (Arm 6) or Dato-DXd (DS-1062a; Arm 7 and 8) treatment
  3. Patients enrolled in Arm 6 only: Previously been diagnosed as + or received HER2-targeted therapy.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
243 participants (actual)

Study arms

  • Experimental
    Arm 1

    durvalumab + paclitaxel

    Drug: Durvalumab · Drug: Paclitaxel

  • Experimental
    Arm 2

    durvalumab + paclitaxel + capivasertib

    Drug: Durvalumab · Drug: Capivasertib · Drug: Paclitaxel

  • Experimental
    Arm 5

    durvalumab + paclitaxel + oleclumab

    Drug: Durvalumab · Drug: Oleclumab · Drug: Paclitaxel

  • Experimental
    Arm 6

    durvalumab + trastuzumab deruxtecan

    Drug: Durvalumab · Drug: Trastuzumab deruxtecan

  • Experimental
    Arm 7

    durvalumab + datopotamab deruxtecan

    Drug: Durvalumab · Drug: Datopotamab deruxtecan

  • Experimental
    Arm 8

    durvalumab + datopotomab deruxtecan (patients with PD-L1 positive status)

    Drug: Durvalumab · Drug: Datopotamab deruxtecan

Interventions

  • Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

    Also known as: MEDI4736

  • Capivasertib oral bid 4-week cycles; 3 weeks on (dosing on days 2,3,4 and 5) and 1 week off

    Also known as: AZD5363

  • Oleclumab iv Every 2 weeks (q2w) for first 2 cycles (days 1 and 15 in cycles 1 and 2), then every 4 weeks (q4w) starting at cycle 3 day 1

    Also known as: MEDI9447

  • Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off

  • Trastuzumab deruxtecan iv 3-week cycles (once weekly) q3w

    Also known as: DS-8201a

  • Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w

    Also known as: Dato-DXd; DS-1062a

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity (DLT) Events

    The occurrence of a severe adverse event (meeting pre-specified criteria) that is at least possibly related to durvalumab and/or the novel oncology therapy in 6 DLT-evaluable patients

    Time frame: From the time of first dose until completion of the first cycle (28 days for Arms 2-5, 21 days for Arms 6-7 (no safety run-in for Arms 1 and 8))

Secondary outcomes

  1. Objective Response Rate (ORR)

    Percentage of evaluable patients with a confirmed Investigator-assessed response of CR (complete response) or PR (partial response). Confirmed response is defined as at least one visit response of CR or PR confirmed by a follow-up scan at least 4 weeks later showing CR or PR.

    Time frame: Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)

  2. Progression-free Survival (PFS)

    Time from date of first dose (at least one study intervention \[durvalumab, paclitxel or novel oncology therapy\]) until the date of objective radiological disease progression using RECIST 1.1 or death (by any cause in the absence of progression)

    Time frame: Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)

  3. Duration of Response (DoR)

    Time from the date of first documented response (which is subsequently confirmed) until the first date of documented progression (PD) or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1). If a patient does not progress following a response, then their DoR will be censored at the last evaluable disease assessment date

    Time frame: Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)

  4. Overall Survival (Count)

    Number of patients with overall survival, the time from date of first dose (at least one study intervention \[durvalumab, paclitxel or novel oncology therapy\]) until the date of death by any cause

    Time frame: From date of first dose until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)

  5. Overall Survival (Duration)

    Time from date of first dose (at least one study intervention \[durvalumab, paclitxel or novel oncology therapy\]) until the date of death by any cause

    Time frame: From date of first dose of IP until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)

  6. Progression-free Survival at 6 Months (PFS6)

    Percentage of patients alive and progression-free at 6 months following date of first dose (at least one study intervention \[durvalumab, paclitxel or novel oncology therapy\])

    Time frame: 6 months following date of first dose

07

Results

Posted Feb 2, 2026
Limitations and caveats
Open-label study with a small patient cohort, not designed for cross-arm efficacy comparison. Efficacy judged by investigator assessment with no BICR.

Participant flow

Data cut-off is 30Jun23 for Arms 1,2,5,6 and 29Nov24 for Arms 7-8

Participant flow — Overall Study
MilestoneArm 1Arm 2Arm 5Arm 6Arm 7Arm 8
Started233133586233
Completed000063
Not completed233133585630
Withdrew: Death14172522283
Withdrew: Ongoing study at time of data cut-off (30jun23 for arms 1-6 and 29nov24 for arms 7-8)895332425
Withdrew: Lost to follow-up010010
Withdrew: Withdrawal by subject143232
Withdrew: Reason unknown000100

Outcome measures

PrimaryDose Limiting Toxicity (DLT) Events

The occurrence of a severe adverse event (meeting pre-specified criteria) that is at least possibly related to durvalumab and/or the novel oncology therapy in 6 DLT-evaluable patients

Time frame:
From the time of first dose until completion of the first cycle (28 days for Arms 2-5, 21 days for Arms 6-7 (no safety run-in for Arms 1 and 8))
Reported as:
Number · Participants
Dose Limiting Toxicity (DLT) Events
ParticipantsArm 1Arm 2Arm 5Arm 6Arm 7Arm 8
Dose Limiting Toxicity (DLT) Events—0000—
SecondaryObjective Response Rate (ORR)

Percentage of evaluable patients with a confirmed Investigator-assessed response of CR (complete response) or PR (partial response). Confirmed response is defined as at least one visit response of CR or PR confirmed by a follow-up scan at least 4 weeks later showing CR or PR.

Time frame:
Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
Reported as:
Number · Percentage of patients
Objective Response Rate (ORR)
Percentage of patientsArm 1Arm 2Arm 5Arm 6Arm 7Arm 8
Objective Response Rate (ORR)56.5 (34.5 to 76.8)54.8 (36.0 to 72.7)51.5 (33.5 to 69.2)62.1 (48.4 to 74.5)79.0 (66.8 to 88.3)81.8 (64.5 to 93.0)
SecondaryProgression-free Survival (PFS)

Time from date of first dose (at least one study intervention \[durvalumab, paclitxel or novel oncology therapy\]) until the date of objective radiological disease progression using RECIST 1.1 or death (by any cause in the absence of progression)

Time frame:
Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsArm 1Arm 2Arm 5Arm 6Arm 7Arm 8
Progression-free Survival (PFS)7.3 (5.4 to 11.3)6.4 (5.4 to 10.3)8.3 (4.8 to 9.3)12.6 (8.4 to 16.3)14.0 (11.0 to 21.1)11.2 (6.9 to 13.8)
SecondaryDuration of Response (DoR)

Time from the date of first documented response (which is subsequently confirmed) until the first date of documented progression (PD) or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1). If a patient does not progress following a response, then their DoR will be censored at the last evaluable disease assessment date

Time frame:
Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
Reported as:
Median · Months
Duration of Response (DoR)
MonthsArm 1Arm 2Arm 5Arm 6Arm 7Arm 8
Duration of Response (DoR)5.6 (3.75 to 26.12)7.9 (3.98 to 14.59)7.8 (5.42 to 17.77)15.2 (8.44 to NA)17.6 (10.51 to 27.27)11.5 (5.16 to NA)
SecondaryOverall Survival (Count)

Number of patients with overall survival, the time from date of first dose (at least one study intervention \[durvalumab, paclitxel or novel oncology therapy\]) until the date of death by any cause

Time frame:
From date of first dose until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)
Reported as:
Count of participants · Participants
Overall Survival (Count)
ParticipantsArm 1Arm 2Arm 5Arm 6Arm 7Arm 8
Died14182522283
Alive at data cut-off895333028
Terminated prior to death143342
SecondaryOverall Survival (Duration)

Time from date of first dose (at least one study intervention \[durvalumab, paclitxel or novel oncology therapy\]) until the date of death by any cause

Time frame:
From date of first dose of IP until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)
Reported as:
Median · Months
Overall Survival (Duration)
MonthsArm 1Arm 2Arm 5Arm 6Arm 7Arm 8
Overall Survival (Duration)30.0 (13.0 to NA)32.6 (12.9 to 40.0)24.8 (18.6 to 31.9)30.3 (18.8 to NA)NA (23.2 to NA)NA (NA to NA)
SecondaryProgression-free Survival at 6 Months (PFS6)

Percentage of patients alive and progression-free at 6 months following date of first dose (at least one study intervention \[durvalumab, paclitxel or novel oncology therapy\])

Time frame:
6 months following date of first dose
Reported as:
Number · Percentage of participants
Progression-free Survival at 6 Months (PFS6)
Percentage of participantsArm 1Arm 2Arm 5Arm 6Arm 7Arm 8
Progression-free Survival at 6 Months (PFS6)56.5 (34.3 to 73.8)52.4 (33.1 to 68.5)65.3 (46.0 to 79.1)75.2 (61.8 to 84.5)79.8 (67.2 to 88.0)78.2 (59.5 to 89.0)

Adverse events

Collected over From the time of signature of informed consent up to 90 days after the last dose of study treatment. If an event starts post this period noted and is considered to be due to a late-onset toxicity to study drug, then it should be reported as an AE/SAE. Maximum duration of approximately 54 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durva + Pac14/23 (60.9%)1/23 (4.3%)22/23 (95.7%)
Durva + Pac + Capi 400mg Bid18/31 (58.1%)11/31 (35.5%)30/31 (96.8%)
Durva + Pac + Olec 3000mg25/33 (75.8%)4/33 (12.1%)32/33 (97%)
Durva + DS-8201a22/58 (37.9%)16/58 (27.6%)57/58 (98.3%)
Durva + Dato-DXd28/62 (45.2%)18/62 (29%)62/62 (100%)
Durva + Dato-DXd (PD-L1 High)3/33 (9.1%)5/33 (15.2%)33/33 (100%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventDurva + PacDurva + Pac + Capi 400mg BidDurva + Pac + Olec 3000mgDurva + DS-8201aDurva + Dato-DXdDurva + Dato-DXd (PD-L1 High)
PneumonitisRespiratory, thoracic and mediastinal disorders1/230/310/335/580/620/33
Febrile neutropeniaBlood and lymphatic system disorders0/232/310/330/580/620/33
PyrexiaGeneral disorders0/232/310/330/580/620/33
PneumoniaInfections and infestations0/230/310/332/584/620/33
Pneumonia viralInfections and infestations1/230/310/330/580/620/33
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/230/310/332/580/621/33
Covid-19Infections and infestations0/230/310/332/580/620/33
Adrenal insufficiencyEndocrine disorders0/231/310/330/580/620/33
OsteonecrosisMusculoskeletal and connective tissue disorders0/231/310/330/580/620/33
Cerebrovascular accidentNervous system disorders0/231/310/330/580/620/33
Most frequent other events
Showing 10 of 107
Most frequent other events
EventDurva + PacDurva + Pac + Capi 400mg BidDurva + Pac + Olec 3000mgDurva + DS-8201aDurva + Dato-DXdDurva + Dato-DXd (PD-L1 High)
StomatitisGastrointestinal disorders4/234/316/339/5843/6227/33
NauseaGastrointestinal disorders11/238/3111/3346/5842/6218/33
DiarrhoeaGastrointestinal disorders3/2321/3111/3313/5810/622/33
AlopeciaSkin and subcutaneous tissue disorders14/2311/3116/3316/5831/6213/33
RashSkin and subcutaneous tissue disorders9/2318/319/337/5821/6213/33
Peripheral sensory neuropathyNervous system disorders13/237/3113/332/582/621/33
FatigueGeneral disorders9/2310/316/3331/5830/6212/33
ConstipationGastrointestinal disorders4/232/315/3320/5831/6210/33
HeadacheNervous system disorders2/235/3112/339/589/623/33
NeutropeniaBlood and lymphatic system disorders3/238/310/3319/583/620/33

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm 1Arm 2Arm 5Arm 6Arm 7Arm 8Total
Median52 (30 to 62)51 (32 to 71)54 (33 to 72)54 (29 to 81)53 (31 to 74)47 (29 to 74)52 (29 to 81)
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Arm 1Arm 2Arm 5Arm 6Arm 7Arm 8Total
Female233133586233240
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1Arm 2Arm 5Arm 6Arm 7Arm 8Total
Hispanic or Latino0002002
Not Hispanic or Latino233133566233238
Unknown or Not Reported0000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm 1Arm 2Arm 5Arm 6Arm 7Arm 8Total
Black or African American0012418
Asian171617161520101
White51515393911124
Other1001417
08

Study locations

32 sites
  • Research Site
    Tucson, Arizona 85715, United States
  • Research Site
    Columbia, Maryland 21044, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Grand Rapids, Michigan 49503, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Williamsburg, Virginia 23188, United States
  • Research Site
    Kelowna, British Columbia V1Y 5L3, Canada
  • Research Site
    London, Ontario N6A 4L6, Canada
  • Research Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Gdansk, 80-952, Poland
  • Research Site
    Krakow, 31-501, Poland
  • Research Site
    Lublin, 20-090, Poland
  • Research Site
    Opole, 45-060, Poland
  • Research Site
    Rzeszów, 35-021, Poland
  • Research Site
    Warsaw, 02-781, Poland
  • Research Site
    Warsaw, 04-141, Poland
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 05505, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Kaohsiung City, 80756, Taiwan
  • Research Site
    Taichung, 40447, Taiwan
  • Research Site
    Tainan, 70403, Taiwan
  • Research Site
    Taipei, 10002, Taiwan
  • Research Site
    Taipei, 112, Taiwan
  • Research Site
    Taoyuan, 333, Taiwan
  • Research Site
    Cambridge, CB2 0QQ, United Kingdom
  • Research Site
    London, EC1M 6BQ, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
  • Research Site
    Oxford, OX3 7LE, United Kingdom
09

References and documents

Publications

  • Schmid P, Im SA, Nowecki Z, Wysocki PJ, Jassem J, Jung KH, Lord S, Armstrong J, Stewart R, Vukovic P, Denduluri N, Park YH. First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial. Nat Cancer. 2026 Jun;7(6):983-992. doi: 10.1038/s43018-026-01181-8. Epub 2026 Jun 8. PubMed 42259988 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Nov 2024, 71 months.

Results were first posted in Feb 2026, 1 year 2 months after primary completion.

Of 70 industry-sponsored phase 1/2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 77. This study's 71 months is above that.

Counting every sponsor, half of 118 studies reached it within 56 months; a quarter within 43 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2018
First posted
Nov 15, 2018
StartActual
Dec 21, 2018
Primary completionActual
Nov 29, 2024
CompletionEst.
Feb 26, 2027
Results first posted
Feb 2, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and site details
1 update, last Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03742102
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 15, 2018
Start date
Dec 21, 2018
Primary completion
Nov 29, 2024
Completion
Feb 26, 2027 (estimated)
Results posted
Feb 2, 2026
Last update
Nov 12, 2026

Study contacts

Peter Schmid, MD, PhD
principal investigator · Barts Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capivasertib · Paclitaxel · Trastuzumab deruxtecan · Datopotamab deruxtecan

Start the discussion